Solubilized phenyl-pyrazole ureas as potent, selective 5-HT2A inverse-agonists and their application as antiplatelet agents

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5486-5489

  Dosa, Peter I ^a   Strah Pleynet, Sonja ^a   Jayakumar, Honnappa ^a   Casper, Martin ^a   Decaire, Marc ^a   Xiong, Yifeng ^a   Lehmann, Juerg ^a   Choi, Karoline ^a   Elwell, Katie ^a   Wong, Amy ^a   Webb, Robert R ^a   Adams, John W ^a   Ramirez, Juan ^a   Richman, Jeremy G ^a   Thomsen, William ^a   Semple, Graeme ^a   Teegarden, Bradley R ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

5 HT2A; Antiplatelet; Antithrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; IODINE 125; MACROGOL 400; PHENYLPYRAZOLE UREA DERIVATIVE; PIMAVANSERIN; POTASSIUM CHANNEL HERG; PYRAZOLE DERIVATIVE; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; UREA DERIVATIVE; VOLINANSERIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; INVERSE AGONISM; MALE; NONHUMAN; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 68949083344     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.073     Document Type: Article

References (20)

1. Hoyer D., Hannon J.P., and Martin G.R. Pharmacol., Biochem. Behav. 71 (2002) 533
2. Sanders-Bush E., Fentress H., and Hazelwood L. Mol. Interventions 3 (2003) 319
3. Sharpley A.L., Solomon R.A., Fernando A.I., da Roza Davis J.M., and Cowen P.J. Psychopharmacology 101 (1990) 568
4. Teegarden B.R., Al-Shamma H., and Xiong Y. Curr. Topics Med. Chem. 8 (2008) 969
5. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., and Krystal J. J. Neuropsych. Clin. Neurosci. 9 (1997) 1
6. Di Pietro N.C., and Seamans J.K. Pharmacopsych. 40 (2007) S27
7. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., Van Giersbergen P.L.M., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., and Widmaier C. J. Pharmacol. Exp. Ther. 277 (1996) 968
8. Vanover K.E., Weiner D.M., Makhay M., Veinbergs I., Gardell L.R., Lameh J., Del Tredici A.L., Piu F., Schiffer H.H., Ott T.R., Burstein E.S., Uldam A.K., Thygesen M.B., Schlienger N., Andersson C.M., Son T.Y., Harvey S.C., Powell S.B., Geyer M.A., Tolf B., Brann M.R., and Davis R.E. J. Pharm. Exp. Ther. 317 (2006) 910
9. Roberts C. Curr. Opin. Invest. Drugs 7 (2006) 653
10. De Clerck F.F., and Herman A.G. Fed Proc. 42 (1983) 228
11. Nagatomo T., Rashid M., Abul Muntasir H., and Komiyama T. Pharmacol. Ther. 104 (2004) 59
12. De Clerck, F. F.; Janssen, P. A. J. Hypertens., 1990, S87.
13. Teegarden, B. R.; Li, H.; Jayakumar, H.; Strah-Pleynet, S.; Dosa, P. I.; Selaya, S. D.; Kato, N.; Elwell, K. H.; Davidson, J.; Cheng, K.; Saldana, H.; Frazer, J. M.; Whelan, K.; Foster, J.; Espitia, S.; Webb, R. R; Beeley, N.R.A.; Kilduff, T.S.; Morairty, S.; Thomsen, W.; Al-Shamma, H., submitted for publication.
14. 2A antagonist see:. Ladduwahetty T., Boase A.L., Mitchinson A., Quin C., Patel S., Chapman K., and MacLeod A.M. Bioorg. Med. Chem. Lett. (2006) 3201
15. Hughes, D. L. In Organic Reactions; Paquette, L. A., Ed.; Wiley: New York, 1992; Vol. 42, pp 335-656.
16. For experimental details, see: Teegarden, B.; Jayakumar, H.; Li, H.; Strah-Pleynet, S.; Dosa, P. I. Preparation of diaryl and arylheteroaryl urea derivatives, in particular pyrazolylphenyl ureas, as 5-HT2A serotonin receptor modulators. WO2005012254, 2005.
17. Teegarden, B.; Xiong, Y.; Strah-Pleynet, S.; Jayakumar, H.; Dosa, P. I.; Feichtinger, K.; Casper, M.; Lehmann, J.; Jones, R. M.; Unett, D. J. Preparation of 3-phenylpyrazole derivatives as modulators of 5-HT2A serotonin receptors for the treatment of related disorders. WO2006055734, 2006.
18. The solubilities of compound 13 (0.25 mg/ml in sodium phosphate buffer and 2.8 mg/ml in 0.01 N HCl) and compound 19 (0.15 mg/ml and 3.3 mg/ml) were similar to that of compound 3.
19. Adams J.W., Ramirez J., Ortuno D., Shi Y., Thomsen W., Richman J.G., Morgan M., Dosa P., Teegarden B.R., Al-Shamma H., Behan D.P., and Connolly D.T. Eur. J. Pharmacol. 586 (2008) 234
20. Inhibition of the hERG channel varied based on the substituents in the compounds, but in general molecules containing the less basic morpholino group, like 54 and 56 (29% at 3 μM), showed less inhibition than those with more basic groups like 32 (90% at 3 μM) and 50 (64% at 1 μM).